| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 65 | 2023 | 437 | 13.050 |
Why?
|
| HIV-1 | 57 | 2023 | 203 | 11.450 |
Why?
|
| beta Catenin | 22 | 2022 | 58 | 8.300 |
Why?
|
| Astrocytes | 25 | 2023 | 126 | 8.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2023 | 111 | 5.250 |
Why?
|
| Virus Replication | 21 | 2021 | 43 | 3.760 |
Why?
|
| Signal Transduction | 22 | 2018 | 387 | 3.570 |
Why?
|
| CD4-Positive T-Lymphocytes | 25 | 2023 | 94 | 2.840 |
Why?
|
| AIDS Dementia Complex | 9 | 2020 | 39 | 2.650 |
Why?
|
| Wnt Signaling Pathway | 6 | 2022 | 30 | 2.620 |
Why?
|
| CD4 Antigens | 7 | 2022 | 29 | 2.440 |
Why?
|
| Wnt Proteins | 6 | 2020 | 21 | 2.340 |
Why?
|
| Brain | 8 | 2023 | 1241 | 2.320 |
Why?
|
| Anti-HIV Agents | 12 | 2023 | 63 | 2.250 |
Why?
|
| Humans | 111 | 2023 | 23156 | 2.070 |
Why?
|
| Gene Expression Regulation | 6 | 2020 | 226 | 2.040 |
Why?
|
| HIV | 9 | 2023 | 40 | 1.940 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2020 | 36 | 1.680 |
Why?
|
| Cytokines | 11 | 2017 | 192 | 1.600 |
Why?
|
| TCF Transcription Factors | 5 | 2020 | 11 | 1.490 |
Why?
|
| Monocytes | 7 | 2023 | 38 | 1.470 |
Why?
|
| Leukocytes, Mononuclear | 12 | 2023 | 47 | 1.470 |
Why?
|
| Macrophages | 7 | 2023 | 79 | 1.460 |
Why?
|
| Nervous System Diseases | 3 | 2023 | 101 | 1.440 |
Why?
|
| CD8 Antigens | 3 | 2022 | 11 | 1.240 |
Why?
|
| Animals | 24 | 2023 | 3270 | 1.220 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2014 | 15 | 1.200 |
Why?
|
| Transcription Factors | 5 | 2014 | 149 | 1.160 |
Why?
|
| Cells, Cultured | 17 | 2023 | 462 | 1.150 |
Why?
|
| Interferon-gamma | 7 | 2014 | 72 | 1.080 |
Why?
|
| Lymphocyte Activation | 13 | 2015 | 76 | 1.070 |
Why?
|
| Virus Latency | 6 | 2022 | 14 | 1.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2020 | 45 | 1.010 |
Why?
|
| Methamphetamine | 3 | 2018 | 22 | 1.000 |
Why?
|
| T-Lymphocytes | 10 | 2012 | 94 | 1.000 |
Why?
|
| HIV Long Terminal Repeat | 9 | 2013 | 17 | 0.910 |
Why?
|
| Adult | 33 | 2021 | 6942 | 0.900 |
Why?
|
| Periodontitis | 3 | 2013 | 3 | 0.900 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2020 | 60 | 0.900 |
Why?
|
| Gene Expression Regulation, Viral | 5 | 2013 | 14 | 0.890 |
Why?
|
| Cell Movement | 2 | 2022 | 77 | 0.840 |
Why?
|
| Fetus | 3 | 2021 | 33 | 0.830 |
Why?
|
| Mice | 11 | 2023 | 1238 | 0.820 |
Why?
|
| Interleukin-7 | 5 | 2016 | 13 | 0.820 |
Why?
|
| Transcription, Genetic | 9 | 2013 | 95 | 0.810 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 87 | 0.810 |
Why?
|
| Flow Cytometry | 11 | 2020 | 100 | 0.800 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 14 | 0.800 |
Why?
|
| Viral Tropism | 1 | 2022 | 4 | 0.750 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 42 | 0.730 |
Why?
|
| Zika Virus Infection | 1 | 2021 | 2 | 0.700 |
Why?
|
| Zika Virus | 1 | 2021 | 2 | 0.700 |
Why?
|
| Immunity, Cellular | 3 | 2020 | 33 | 0.690 |
Why?
|
| Arabs | 3 | 2020 | 8 | 0.690 |
Why?
|
| Receptors, IgG | 1 | 2020 | 8 | 0.660 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2020 | 2 | 0.660 |
Why?
|
| Interleukin-8 | 1 | 2020 | 14 | 0.660 |
Why?
|
| Cell Line | 11 | 2020 | 242 | 0.650 |
Why?
|
| Depression | 2 | 2021 | 383 | 0.650 |
Why?
|
| Hepatocyte Nuclear Factors | 1 | 2020 | 2 | 0.650 |
Why?
|
| Virus Release | 1 | 2020 | 3 | 0.650 |
Why?
|
| Glycoproteins | 1 | 2020 | 41 | 0.650 |
Why?
|
| Prevalence | 6 | 2020 | 380 | 0.640 |
Why?
|
| Central Nervous System Stimulants | 3 | 2018 | 39 | 0.640 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 34 | 0.640 |
Why?
|
| Interleukin-6 | 1 | 2020 | 70 | 0.630 |
Why?
|
| Dentin Sensitivity | 1 | 2020 | 1 | 0.630 |
Why?
|
| Glutamic Acid | 3 | 2020 | 21 | 0.630 |
Why?
|
| Central Nervous System | 3 | 2020 | 47 | 0.610 |
Why?
|
| Young Adult | 7 | 2020 | 1654 | 0.610 |
Why?
|
| Viral Load | 11 | 2021 | 70 | 0.590 |
Why?
|
| Tooth Erosion | 1 | 2018 | 1 | 0.580 |
Why?
|
| Tooth Wear | 1 | 2018 | 1 | 0.580 |
Why?
|
| Biomarkers | 6 | 2021 | 481 | 0.580 |
Why?
|
| Hippocampus | 1 | 2020 | 196 | 0.580 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 368 | 0.560 |
Why?
|
| Adolescent | 10 | 2020 | 1883 | 0.560 |
Why?
|
| Female | 28 | 2021 | 13117 | 0.550 |
Why?
|
| Phagocytosis | 1 | 2017 | 20 | 0.540 |
Why?
|
| Plasma | 1 | 2017 | 13 | 0.530 |
Why?
|
| Mice, SCID | 5 | 2022 | 39 | 0.520 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2021 | 49 | 0.520 |
Why?
|
| Thymus Gland | 5 | 2004 | 11 | 0.510 |
Why?
|
| Hepacivirus | 5 | 2016 | 32 | 0.510 |
Why?
|
| Genitalia, Female | 4 | 2001 | 13 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 4 | 2022 | 15 | 0.500 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 243 | 0.500 |
Why?
|
| Transcriptional Activation | 2 | 2011 | 27 | 0.500 |
Why?
|
| Mice, Inbred NOD | 4 | 2022 | 24 | 0.490 |
Why?
|
| Male | 19 | 2020 | 12636 | 0.490 |
Why?
|
| Cell Communication | 2 | 2014 | 21 | 0.480 |
Why?
|
| Hepatitis C | 3 | 2016 | 42 | 0.480 |
Why?
|
| DNA-Binding Proteins | 3 | 2017 | 231 | 0.480 |
Why?
|
| STAT3 Transcription Factor | 2 | 2014 | 11 | 0.450 |
Why?
|
| RNA, Viral | 9 | 2010 | 44 | 0.450 |
Why?
|
| Down-Regulation | 2 | 2012 | 87 | 0.450 |
Why?
|
| Neurons | 1 | 2017 | 273 | 0.440 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 11 | 0.430 |
Why?
|
| Quality of Life | 2 | 2022 | 564 | 0.430 |
Why?
|
| Cell Differentiation | 2 | 2023 | 124 | 0.420 |
Why?
|
| Middle Aged | 17 | 2021 | 7964 | 0.410 |
Why?
|
| Periodontal Diseases | 1 | 2013 | 1 | 0.410 |
Why?
|
| Mice, Knockout | 4 | 2020 | 276 | 0.410 |
Why?
|
| Oral Health | 1 | 2013 | 1 | 0.410 |
Why?
|
| Pyramidal Cells | 3 | 2019 | 34 | 0.400 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 60 | 0.400 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 15 | 0.400 |
Why?
|
| Estradiol | 1 | 2013 | 52 | 0.390 |
Why?
|
| Membrane Proteins | 1 | 2014 | 140 | 0.390 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 73 | 0.390 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 1 | 0.390 |
Why?
|
| Menstrual Cycle | 3 | 2001 | 19 | 0.380 |
Why?
|
| Prefrontal Cortex | 3 | 2019 | 104 | 0.380 |
Why?
|
| Antigens, Viral | 1 | 2012 | 9 | 0.370 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 16 | 0.370 |
Why?
|
| Up-Regulation | 5 | 2011 | 143 | 0.370 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2002 | 16 | 0.360 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 775 | 0.360 |
Why?
|
| Antigens, CD | 5 | 2017 | 49 | 0.360 |
Why?
|
| Immunophenotyping | 7 | 2007 | 28 | 0.350 |
Why?
|
| Neurodegenerative Diseases | 1 | 2012 | 98 | 0.350 |
Why?
|
| Mental Disorders | 1 | 2012 | 134 | 0.340 |
Why?
|
| Killer Cells, Natural | 4 | 2007 | 40 | 0.330 |
Why?
|
| Receptors, CXCR4 | 6 | 2007 | 17 | 0.320 |
Why?
|
| HIV Protease Inhibitors | 2 | 2002 | 4 | 0.320 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 2 | 2022 | 5 | 0.310 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2009 | 6 | 0.310 |
Why?
|
| Transfection | 4 | 2016 | 115 | 0.310 |
Why?
|
| Transcription Factor 4 | 4 | 2014 | 8 | 0.300 |
Why?
|
| Virus Activation | 3 | 2022 | 10 | 0.300 |
Why?
|
| Risk Factors | 4 | 2020 | 2019 | 0.280 |
Why?
|
| NFATC Transcription Factors | 2 | 2006 | 9 | 0.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2003 | 8 | 0.280 |
Why?
|
| Oman | 2 | 2020 | 2 | 0.270 |
Why?
|
| Base Sequence | 5 | 2012 | 99 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 85 | 0.270 |
Why?
|
| Schizophrenia | 2 | 2021 | 46 | 0.260 |
Why?
|
| Receptors, Prostaglandin | 1 | 2007 | 1 | 0.260 |
Why?
|
| Receptors, CCR5 | 5 | 2007 | 13 | 0.260 |
Why?
|
| Th2 Cells | 1 | 2007 | 14 | 0.260 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 14 | 0.260 |
Why?
|
| Repressor Proteins | 1 | 2007 | 33 | 0.260 |
Why?
|
| Spleen | 2 | 2017 | 26 | 0.250 |
Why?
|
| Calcium Channels, L-Type | 2 | 2017 | 52 | 0.250 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 3 | 2004 | 4 | 0.240 |
Why?
|
| Age Factors | 3 | 2020 | 650 | 0.240 |
Why?
|
| RNA, Messenger | 4 | 2019 | 283 | 0.240 |
Why?
|
| Rats | 5 | 2020 | 623 | 0.240 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 177 | 0.230 |
Why?
|
| Cognition | 2 | 2023 | 1025 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 73 | 0.230 |
Why?
|
| Apoptosis | 2 | 2022 | 194 | 0.220 |
Why?
|
| Mitochondria | 2 | 2022 | 55 | 0.220 |
Why?
|
| Vero Cells | 2 | 2021 | 7 | 0.220 |
Why?
|
| Aging | 4 | 2020 | 1175 | 0.210 |
Why?
|
| Virus Internalization | 2 | 2021 | 18 | 0.210 |
Why?
|
| Vagina | 2 | 2001 | 31 | 0.210 |
Why?
|
| NF-kappa B | 3 | 1999 | 100 | 0.210 |
Why?
|
| Immunomagnetic Separation | 1 | 2004 | 2 | 0.210 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2004 | 12 | 0.210 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 526 | 0.200 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 30 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 106 | 0.200 |
Why?
|
| Binding Sites | 3 | 2012 | 67 | 0.200 |
Why?
|
| Antigens, CD1 | 1 | 2003 | 1 | 0.190 |
Why?
|
| Protein Binding | 3 | 2012 | 112 | 0.190 |
Why?
|
| Microbiota | 1 | 2023 | 65 | 0.190 |
Why?
|
| HLA-DR Antigens | 3 | 2014 | 11 | 0.190 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.190 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2022 | 2 | 0.190 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2022 | 2 | 0.190 |
Why?
|
| Proviruses | 1 | 2022 | 3 | 0.190 |
Why?
|
| Receptors, CXCR3 | 1 | 2022 | 4 | 0.190 |
Why?
|
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2022 | 2 | 0.180 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1999 | 8 | 0.180 |
Why?
|
| Trophoblasts | 1 | 2002 | 2 | 0.180 |
Why?
|
| Immunoassay | 2 | 2017 | 33 | 0.180 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 124 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 112 | 0.180 |
Why?
|
| HIV Seropositivity | 2 | 2021 | 50 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2012 | 132 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2022 | 70 | 0.170 |
Why?
|
| Osteoporosis | 1 | 2022 | 73 | 0.170 |
Why?
|
| Cellular Senescence | 2 | 2020 | 15 | 0.170 |
Why?
|
| Osteocalcin | 1 | 2021 | 26 | 0.170 |
Why?
|
| Pilot Projects | 3 | 2013 | 369 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 31 | 0.170 |
Why?
|
| Vitamin D | 1 | 2021 | 28 | 0.170 |
Why?
|
| Cell Separation | 1 | 2020 | 21 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 130 | 0.170 |
Why?
|
| Kidney | 1 | 2021 | 142 | 0.160 |
Why?
|
| United States | 3 | 2018 | 1796 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 66 | 0.160 |
Why?
|
| DNA Virus Infections | 1 | 2020 | 4 | 0.160 |
Why?
|
| RNA Virus Infections | 1 | 2020 | 4 | 0.160 |
Why?
|
| RNA Viruses | 1 | 2020 | 4 | 0.160 |
Why?
|
| Salicylates | 1 | 2020 | 6 | 0.160 |
Why?
|
| DNA Viruses | 1 | 2020 | 5 | 0.160 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 13 | 0.160 |
Why?
|
| Dentin | 1 | 2020 | 1 | 0.160 |
Why?
|
| Saudi Arabia | 1 | 2020 | 2 | 0.160 |
Why?
|
| Viral Fusion Proteins | 1 | 2020 | 15 | 0.160 |
Why?
|
| Neurocognitive Disorders | 1 | 2020 | 11 | 0.160 |
Why?
|
| Culture Media, Conditioned | 2 | 2014 | 18 | 0.150 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2019 | 6 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2020 | 66 | 0.150 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2019 | 11 | 0.150 |
Why?
|
| Gene Expression | 4 | 2017 | 180 | 0.150 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2010 | 3 | 0.150 |
Why?
|
| Solubility | 4 | 2006 | 18 | 0.150 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2018 | 3 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 22 | 0.140 |
Why?
|
| Potassium Channels | 1 | 2018 | 36 | 0.140 |
Why?
|
| DNA | 1 | 2018 | 94 | 0.140 |
Why?
|
| Cell Division | 4 | 2004 | 80 | 0.140 |
Why?
|
| Transcription Factor AP-1 | 4 | 1999 | 16 | 0.140 |
Why?
|
| Phenotype | 3 | 2020 | 260 | 0.140 |
Why?
|
| 5' Untranslated Regions | 1 | 1998 | 1 | 0.140 |
Why?
|
| In Vitro Techniques | 3 | 2004 | 152 | 0.140 |
Why?
|
| Virus Integration | 2 | 2013 | 6 | 0.140 |
Why?
|
| Calcium | 2 | 2020 | 370 | 0.140 |
Why?
|
| Interleukin-15 | 1 | 1998 | 8 | 0.140 |
Why?
|
| Antibiosis | 1 | 1998 | 2 | 0.140 |
Why?
|
| HIV-2 | 1 | 1998 | 8 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 1998 | 33 | 0.140 |
Why?
|
| Prosthodontics | 1 | 2017 | 1 | 0.130 |
Why?
|
| Oral Surgical Procedures, Preprosthetic | 1 | 2017 | 1 | 0.130 |
Why?
|
| Chronic Periodontitis | 1 | 2017 | 1 | 0.130 |
Why?
|
| Esthetics, Dental | 1 | 2017 | 2 | 0.130 |
Why?
|
| Dental Implantation | 1 | 2017 | 2 | 0.130 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 17 | 0.130 |
Why?
|
| California | 1 | 2017 | 36 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 20 | 0.130 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 24 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 23 | 0.130 |
Why?
|
| Dental Implants | 1 | 2017 | 9 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 28 | 0.130 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Morpholinos | 1 | 2016 | 3 | 0.130 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 48 | 0.130 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 19 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 2 | 2008 | 42 | 0.120 |
Why?
|
| Dementia | 1 | 2021 | 415 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 39 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 76 | 0.120 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2016 | 22 | 0.120 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 1036 | 0.120 |
Why?
|
| Heterografts | 1 | 2015 | 16 | 0.120 |
Why?
|
| Coinfection | 1 | 2016 | 20 | 0.120 |
Why?
|
| DNA, Viral | 3 | 2020 | 39 | 0.120 |
Why?
|
| Coculture Techniques | 3 | 2006 | 31 | 0.120 |
Why?
|
| Interleukin-4 | 2 | 2007 | 16 | 0.110 |
Why?
|
| Claudins | 1 | 2015 | 5 | 0.110 |
Why?
|
| Nebraska | 1 | 2014 | 1 | 0.110 |
Why?
|
| Acyltransferases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 916 | 0.110 |
Why?
|
| Leukocytes | 1 | 2014 | 29 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2012 | 22 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 1998 | 163 | 0.100 |
Why?
|
| Colon | 1 | 2015 | 112 | 0.100 |
Why?
|
| CD4-CD8 Ratio | 2 | 2004 | 4 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 5 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 6 | 0.100 |
Why?
|
| Stem Cells | 1 | 2014 | 34 | 0.100 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Tooth Loss | 1 | 2013 | 1 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 23 | 0.100 |
Why?
|
| Dental Care | 1 | 2013 | 2 | 0.100 |
Why?
|
| Periodontal Pocket | 1 | 2013 | 2 | 0.100 |
Why?
|
| Periodontal Attachment Loss | 1 | 2013 | 3 | 0.100 |
Why?
|
| Dental Caries | 1 | 2013 | 5 | 0.100 |
Why?
|
| Leukocyte Common Antigens | 2 | 2005 | 6 | 0.100 |
Why?
|
| Alveolar Bone Loss | 1 | 2013 | 4 | 0.100 |
Why?
|
| HIV Core Protein p24 | 3 | 2003 | 10 | 0.100 |
Why?
|
| Self Concept | 1 | 2013 | 38 | 0.100 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 15 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 109 | 0.100 |
Why?
|
| Africa, Northern | 1 | 2013 | 1 | 0.100 |
Why?
|
| Gingivitis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Periodontal Index | 1 | 2013 | 2 | 0.100 |
Why?
|
| Middle East | 1 | 2013 | 3 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 83 | 0.100 |
Why?
|
| Disease Progression | 2 | 2017 | 543 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2013 | 91 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2013 | 105 | 0.100 |
Why?
|
| Cysteine | 1 | 2012 | 5 | 0.100 |
Why?
|
| Gene Products, tat | 1 | 2012 | 4 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 19 | 0.100 |
Why?
|
| Luciferases | 1 | 2012 | 25 | 0.100 |
Why?
|
| Behavior | 1 | 2012 | 21 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 36 | 0.100 |
Why?
|
| Point Mutation | 1 | 2012 | 25 | 0.100 |
Why?
|
| Glioma | 1 | 2012 | 16 | 0.100 |
Why?
|
| Plasmids | 1 | 2012 | 42 | 0.100 |
Why?
|
| Vibrio cholerae | 1 | 1992 | 2 | 0.100 |
Why?
|
| Melanins | 1 | 1992 | 6 | 0.090 |
Why?
|
| Smoking | 1 | 2013 | 163 | 0.090 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 7 | 0.090 |
Why?
|
| Cell Culture Techniques | 2 | 2003 | 31 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 71 | 0.090 |
Why?
|
| Zidovudine | 2 | 2003 | 13 | 0.090 |
Why?
|
| Disease Reservoirs | 1 | 2011 | 9 | 0.090 |
Why?
|
| Lamivudine | 2 | 2023 | 7 | 0.090 |
Why?
|
| Fas Ligand Protein | 1 | 2011 | 6 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2012 | 40 | 0.090 |
Why?
|
| Haplotypes | 1 | 2011 | 43 | 0.090 |
Why?
|
| Virus Shedding | 2 | 2001 | 6 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 7 | 0.090 |
Why?
|
| Oximes | 1 | 2011 | 1 | 0.090 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2008 | 5 | 0.090 |
Why?
|
| Indoles | 1 | 2011 | 32 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 162 | 0.080 |
Why?
|
| bcl-X Protein | 1 | 2010 | 5 | 0.080 |
Why?
|
| Lithium Chloride | 1 | 2010 | 3 | 0.080 |
Why?
|
| Bone Density | 2 | 2022 | 146 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 12 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2007 | 5 | 0.080 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 55 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 429 | 0.080 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2007 | 6 | 0.080 |
Why?
|
| Dendritic Cells | 2 | 2007 | 28 | 0.080 |
Why?
|
| AIDS Vaccines | 1 | 2009 | 2 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 279 | 0.070 |
Why?
|
| Women's Health | 1 | 2010 | 174 | 0.070 |
Why?
|
| Action Potentials | 2 | 2019 | 83 | 0.070 |
Why?
|
| Lithium | 1 | 2008 | 19 | 0.070 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 1998 | 35 | 0.070 |
Why?
|
| Time Factors | 2 | 2002 | 1264 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2004 | 569 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 18 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 53 | 0.070 |
Why?
|
| Reverse Transcription | 1 | 2007 | 1 | 0.070 |
Why?
|
| Immunotherapy | 2 | 1998 | 50 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 163 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2007 | 8 | 0.060 |
Why?
|
| Membrane Potentials | 2 | 2018 | 168 | 0.060 |
Why?
|
| Aged | 2 | 2017 | 7638 | 0.060 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 1 | 0.060 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2006 | 1 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2006 | 6 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2006 | 21 | 0.060 |
Why?
|
| Interleukin-16 | 1 | 2006 | 6 | 0.060 |
Why?
|
| Lymphocyte Subsets | 2 | 2008 | 6 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 168 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2006 | 1463 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2012 | 22 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2005 | 33 | 0.060 |
Why?
|
| Lymphopoiesis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2004 | 5 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2004 | 51 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 19 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 40 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 4 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2003 | 13 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2003 | 7 | 0.050 |
Why?
|
| Child | 2 | 2004 | 1160 | 0.050 |
Why?
|
| Bacteria | 1 | 2023 | 61 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 56 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2023 | 41 | 0.050 |
Why?
|
| Epitopes | 1 | 2003 | 39 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 15 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2003 | 21 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2012 | 1406 | 0.050 |
Why?
|
| Antigens, CD1d | 1 | 2003 | 2 | 0.050 |
Why?
|
| Clone Cells | 1 | 2003 | 11 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 14 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2002 | 10 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 13 | 0.050 |
Why?
|
| Intestines | 1 | 2003 | 77 | 0.050 |
Why?
|
| Immune System | 1 | 2002 | 10 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 67 | 0.050 |
Why?
|
| Genes, gag | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, pol | 1 | 2002 | 1 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 24 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 15 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 17 | 0.040 |
Why?
|
| Therapeutic Irrigation | 2 | 1998 | 44 | 0.040 |
Why?
|
| Second Messenger Systems | 2 | 1998 | 6 | 0.040 |
Why?
|
| Phytohemagglutinins | 1 | 2001 | 4 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2022 | 107 | 0.040 |
Why?
|
| Biological Factors | 1 | 2001 | 3 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2011 | 40 | 0.040 |
Why?
|
| Immunity | 1 | 2001 | 10 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2001 | 23 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 86 | 0.040 |
Why?
|
| Models, Biological | 1 | 2002 | 302 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2000 | 2 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 2000 | 2 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2000 | 3 | 0.040 |
Why?
|
| Follicular Phase | 1 | 2000 | 2 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 2000 | 8 | 0.040 |
Why?
|
| Luteal Phase | 1 | 2000 | 5 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2000 | 12 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 26 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 1103 | 0.040 |
Why?
|
| Interleukins | 1 | 2000 | 21 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2021 | 73 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1998 | 313 | 0.040 |
Why?
|
| Indinavir | 1 | 2000 | 1 | 0.040 |
Why?
|
| Saliva | 1 | 2000 | 47 | 0.040 |
Why?
|
| DNA Replication | 1 | 2020 | 10 | 0.040 |
Why?
|
| DNA Primers | 1 | 2000 | 49 | 0.040 |
Why?
|
| Virion | 1 | 2020 | 12 | 0.040 |
Why?
|
| Glutamine | 1 | 2020 | 6 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2014 | 163 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 59 | 0.040 |
Why?
|
| Glucose | 1 | 2020 | 45 | 0.040 |
Why?
|
| Mycoplasma | 1 | 1999 | 2 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1999 | 8 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2020 | 83 | 0.040 |
Why?
|
| Chemical Fractionation | 1 | 1999 | 4 | 0.040 |
Why?
|
| Vaginosis, Bacterial | 1 | 1999 | 16 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 1998 | 18 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2000 | 485 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2006 | 2942 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 1998 | 2 | 0.040 |
Why?
|
| Chromatin | 1 | 1998 | 14 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 1 | 1998 | 5 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1998 | 50 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 1998 | 24 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 6 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1998 | 47 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2017 | 17 | 0.030 |
Why?
|
| Dental Restoration Failure | 1 | 2017 | 2 | 0.030 |
Why?
|
| Smiling | 1 | 2017 | 2 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 49 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 1511 | 0.030 |
Why?
|
| Mutation | 1 | 1998 | 329 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2016 | 97 | 0.030 |
Why?
|
| Natural Killer T-Cells | 1 | 2016 | 3 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 7 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 175 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 179 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 69 | 0.030 |
Why?
|
| Leukocyte Transfusion | 1 | 2014 | 4 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 9 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 11 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2014 | 20 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 30 | 0.030 |
Why?
|
| Betaine | 1 | 1992 | 1 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1992 | 2 | 0.020 |
Why?
|
| Proline | 1 | 1992 | 10 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1992 | 17 | 0.020 |
Why?
|
| Culture Media | 1 | 1992 | 28 | 0.020 |
Why?
|
| Temperature | 1 | 1992 | 55 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 125 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1992 | 31 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2012 | 6 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2012 | 15 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2012 | 7 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 5 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 11 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 34 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 56 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 110 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 176 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 43 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 363 | 0.020 |
Why?
|
| Infant | 2 | 2003 | 483 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2003 | 537 | 0.020 |
Why?
|
| Hepatitis C Antibodies | 1 | 2008 | 4 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 4 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2007 | 30 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 50 | 0.020 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Perforin | 1 | 2006 | 2 | 0.020 |
Why?
|
| CpG Islands | 1 | 2006 | 43 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 21 | 0.010 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2003 | 1 | 0.010 |
Why?
|
| Telomere | 1 | 2003 | 6 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2003 | 11 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 30 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2002 | 1 | 0.010 |
Why?
|
| L-Selectin | 1 | 2002 | 7 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 374 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 324 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 38 | 0.010 |
Why?
|
| Protein Kinase C beta | 1 | 1998 | 8 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 161 | 0.010 |
Why?
|
| Cell Lineage | 1 | 1998 | 25 | 0.010 |
Why?
|
| Heating | 1 | 1997 | 4 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 9 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1997 | 18 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 21 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 192 | 0.010 |
Why?
|